When it comes to pharma, there is another pick in Shilpa Medicare. With one time 52 week high of around 1246 it has come down to the level of 432 because of volatile market conditions or on its own. With small equity capital of just 7.71 crore and massive reserves of around 550 crore, it has a very decent market cap of 3331 crore with dividend paying history. It would be seen that its price to earning matches with the industry pe and it stands as a clear buy at current levels.
With debt equity ratio of less than 1 (0.12% coming to yet lower band), it has achieved the ROE of 14% on an average during the past five years. Unless other industries, it has clocked better sales and net profit for Dec 2015 when compared with Sept 2015 results.
With promoters holding around 53% of total shares and presence of mutual fund, FIs, central government and QFIs it makes a best choice for patient investors.
Investor friendly company with an eye on growth too if the CRR and DPR ratio is any indicator.
Invest with time horizon and enjoy.